Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for persistent fluid in exudative age-related macular degeneration
ACTRN12612000666820Phase 4Recruiting
- Sponsor
- DeepSeq.AI
- Start
- Jul 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by DeepSeq.AI. Primary endpoint: Anatomic and visual stability at Week 24. Started Jul 2012; status: recruiting.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12612000666820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000666820.